

# Maryam Sarraf-Yazdy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8515797/maryam-sarraf-yazdy-publications-by-citations.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

350

citations

9

h-index

18

g-index

26

ext. papers

457

ext. citations

3.7

avg, IF

2.77

L-index

#	Paper	IF	Citations
26	Variation of biophysical parameters of the skin with age, gender, and body region. <i>Scientific World Journal, The</i> , <b>2012</b> , 2012, 386936	2.2	122
25	Pre-operative assessment of basal cell carcinoma dimensions using high frequency ultrasonography and its correlation with histopathology. <i>Skin Research and Technology</i> , <b>2013</b> , 19, e132-8	1.9	51
24	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3589-3596	12.9	43
23	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4264-4270	12.9	37
22	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , <b>2019</b> , 3, 1568-1573	7.8	18
21	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. <i>Blood</i> , <b>2019</b> , 133, 121-129	2.2	13
20	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , <b>2019</b> , 134, 4311-4311	2.2	12
19	Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1916326	10.4	12
18	Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 637-644	2	10
17	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , <b>2021</b> , 106, 1932-1942	6.6	8
16	Allergic contact dermatitis to metal allergens in Iran. <i>International Journal of Dermatology</i> , <b>2013</b> , 52, 1513-8	1.7	7
15	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1129-1138	2.2	7
14	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , <b>2021</b> , 5, 2852-2862	7.8	5
13	Current challenges in the management of follicular lymphoma. <i>International Journal of Hematologic Oncology</i> , <b>2017</b> , 6, 13-24	1	1
12	Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 773-780	2.8	1
11	Targeting Biology in Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2019</b> , 33, 727-738	3.1	1
10	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , <b>2020</b> , 136, 49-50	2.2	1

9	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , <b>2019</b> , 134, 1756-1756	2.2	1
8	Impact of obinutuzumab alone and in combination for follicular lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , <b>2017</b> , 7, 73-83	2.6	0
7	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. <i>Blood</i> , <b>2018</b> , 132, 4759-4759	2.2	0
6	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , <b>2020</b> , 136, 46-49	2.2	
5	Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease. <i>Blood</i> , <b>2019</b> , 134, 2813-2813	2.2	
4	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 1553-1553	2.2	
3	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , <b>2019</b> , 134, 3048-3048	2.2	
2	Long-term follow-up of patients (Pts) treated with bendamustine (B) for lymphoid malignancies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14027-e14027	2.2	
1	Molecular characterization of early vs. late onset gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 46-46	2.2	